Covid-19: Nepal asks India to facilitate supply of vaccine

Published On 2021-04-11 04:00 GMT | Update On 2021-04-11 04:00 GMT

Kathmandu: Nepal's Minister for Foreign Affairs Pradeep Kumar Gyawali on Friday called his Indian counterpart S Jaishankar and requested him to facilitate the supply of the vaccine against the COVID-19.

Gyawali had a telephone conversation with Jaishankar to discuss the cooperation in fighting the coronavirus pandemic, the Foreign Ministry here said.

'During the conversation, the two sides exchanged views on intensifying efforts to fight the COVID-19 pandemic.

'Foreign Minister Gyawali expressed sincere thanks to the Government of India for supporting Nepal in its fight against the COVID-19 pandemic, including through the generous gift of one million doses of COVISHIELD,' it said in a statement.

Gyawali requested Jaishankar for the necessary facilitation for the supply of the vaccine to Nepal to continue administering the second dose for people at highest risk.

'The External Affairs Minister of India assured him of a continued support to Nepal in its fight against the pandemic, including through the supply of vaccines,' the statement added.

Oxford-AstraZeneca's Covishield is being manufactured by Pune-based Serum Institute of India (SII) which has collaborated with Oxford University and pharmaceutical company AstraZeneca for making the vaccine.

Nepal's Health Ministry has recommended to restrict any gathering involving more than 25 people at a time in a bid to arrest the spread of the coronavirus.

The ministry has also recommended halting physical classes of schools and colleges.

In the last 24 hours, Nepal detected 332 new COVID-19 cases, taking the national tally to 279,100.

Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Covid-19: Nepal asks India to facilitate supply of vaccine

Similar News

Keeping Medicines Without Licence Amounts to 'Offer for Sale', HC Upholds Chemist's Conviction

Lupin Manufacturing Solutions: Empagliflozin API gets CADIFA approval from ANVISA, Brazil

Zydus Foundation Vice Chairperson Meha Patel appointed as Member of CII National Committee on Art & Culture for 2025-26

Eris Lifesciences Secures CDSCO Panel Nod to Conduct BE Study on Dapagliflozin, Pioglitazone, Metformin FDC

Delhi to form special committee to crush fake medicine racket

Roche Pharma teams up with 10 Govt Hospitals to power up clinical trial capacities in India

AstraZeneca's Proposal to Increase Sample Size in Zibotentan-Dapagliflozin Global Trial Gets SEC Nod

Govt Allows Stickering, Orders New MRPs Post GST Reduction, AiMeD Welcomes Directive